Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer

ATTRACTION-5: Nivolumab plus chemotherapy as postoperative adjuvant treatment for pStage III G/GEJ cancer

NSIA and Nigeria to improve treatment for Nigerians through the building of new cancer centres

NSIA and BVGH aim to improve patient outcomes and access to quality cancer care

Optimising cervical cancer care in Nigeria

Tackling low-volumes of clinical trials in Africa

Management of prostate cancer in Africa: Looking to the future

Time toxicity: the burden on cancer patients

The time toxicity of cancer care

The current status of multiple myeloma diagnosis and treatment

Decision making in paediatric oncology

Choosing cancer medicines wisely in Africa